Name
Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+FL
Speakers
Ralph Boccia, MD , Center for Cancer and Blood Disorder
Content Presented on Behalf of
Product Theater Sponsor: Genmab
Session Type
Product Theater
Date
Tuesday, March 4, 2025
Start Time
1:15 PM
End Time
1:45 PM
Room#/Location
Prince Georges Exhibit Hall A/B
Learning Outcomes
To Learn about Epkinly for patients with 3L+ Diffuse Large B Cell Lymphoma and 3L+ Follicular Lymphoma including:
• Current treatment landscape
• Clinical profile
• Safety information
• Dosing and Administration
CE/CME Session
Non-CE Session
Session Currently Live
Add To Calendar